Tag: HepC Info Updates

CATIE HepCinfo Update 6.8

In this issue Two new FDA warnings issued for simeprevir FDA grants new breakthrough therapy designation for grazoprevir and elbasvir Good adherence to Harvoni shown in two clinical trials Two new FDA warnings issued for simeprevir Two new warnings for simeprevir (Galexos) have been issued by the U.S. Food and Drug Administration (FDA) about: a… Read more »

CATIE’s HepCInfo Updates 6.2

New and Noteworthy Screening Canadians born between 1945 and 1965 could be cost effective According to a modelling study, one-time screening for people 25 to 64 or 45 to 64 years of age could be cost-effective, reported researchers in the Canadian Medical Association Journal. For both age ranges the researchers modelled four options: No screening… Read more »

New and Noteworthy Hep C infections due to unsafe medical procedures falling in low and middle-income countries The number of Hep C infections in low and middle-income countries acquired due to unsafe medical injections fell by an estimated 91% between 2000 and 2010, reported Canadian researchers in PLOS One. In 2000, the World Health Organization… Read more »

CATIE’s HepC Info Update 5.9

New and Noteworthy TreatmentUpdate 202: Hepatitis C Virus The latest issue of TreatmentUpdate contains in-depth information about Hep C treatments that have recently been approved by Health Canada, including sofosbuvir (Sovaldi) and simeprevir (Galexos), and new Hep C treatments in development. More surprises ahead for hepatitis C therapy Abbvie’s potent combination Simeprevir – potential drug… Read more »

CATIE’s HepCInfo Update 5.8

New and Noteworthy Staying Safe Intervention reduces risk for Hep C and HIV in people who inject drugs An evaluation of an intervention designed to prevent the transmission of Hep C and HIV among people who inject drugs has shown decreases in behaviours considered a risk for contracting Hep C and HIV. This strengths-based intervention… Read more »